Cannabis Bioscience International Holdings, Inc. (CBIH)
| Previous close | 0.0009 |
| Open | 0.0009 |
| Bid | 0.0008 x 0 |
| Ask | 0.0009 x 0 |
| Day's range | 0.0008 - 0.0009 |
| 52-week range | 0.0003 - 0.0020 |
| Volume | |
| Avg. volume | 12,714,562 |
| Market cap | 8.305M |
| Beta (5Y monthly) | -0.12 |
| PE ratio (TTM) | 0.08 |
| EPS (TTM) | 0.0100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireCBIH Pursues Regulatory Compliance and Market Growth with Essential Licensing Applications
HOUSTON, July 15, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS:CBIH) has initiated a strategic move to expand its presence in the cannabis market by filing applications for crucial licenses covering the manufacturing, production, and retail components of its cannabis product range. Preparations are underway for the production and distribution of our products, and continue to foster revenue expansion, which could only be achieved through the practical application o
- GlobeNewswire
CBIH Charts Path to Future Leadership in Cannabis Medicine
A letter from our desk HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Since the start of the year, Cannabis Bioscience International Holdings (OTCMKTS: CBIH) has embarked on a transformative journey involving merger opportunities, patent registrations, and company valuation. As we transition into the second half of the year, we aim to address and clarify certain aspects from our previous communications. From our desks - Rosangel Andrades and Jennifer Salguero. In the realm of medicine, patent requir
- GlobeNewswire
CBIH advances Cancer Care with Novel Cannabis Patents for Breast and Pancreatic Cancers
HOUSTON, July 01, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is excited to announce the submission of our inaugural pair of patents, focusing on novel treatment methodologies for breast and pancreatic cancers, for legal review and subsequent registration. Our dedicated scientific team has invested countless hours in research, culminating in the development of innovative treatment approaches specifically designed to tackle breast and pancreatic cancers. Th
